Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

Open access
Navid, Fariba, Sondel, Paul M., Barfield, Raymond, Shulkin, Barry L., Kaufman, Robert A., Allay, Jim A., Gan, Jacek, Hutson, Paul, Seo, Songwon, Kim, KyungMann, Goldberg, Jacob, Hank, Jacquelyn A., Billups, Catherine A., Wu, Jianrong, Furman, Wayne L., McGregor, Lisa M., Otto, Mario, Gillies, Stephen D., Handgretinger, Rupert, Santana, Victor M. · 2014 · Journal of Clinical Oncology

Abstract

Purpose: The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related toxicities that may be partially mediated by complement activation. We report the results of a phase I trial to determine the maximum-tolerated dose (MTD), safety profile, and pharmacokinetics of hu14.18K322A, a humanized anti-GD2 mAb with a single point mutation (K322A) that reduces complement-dependent lysis. Patients and Methods: Eligible patients with refractory or recurrent neuroblastoma received escalating doses of hu14.18K322A ranging from 2 to 70 mg/m 2 per day for 4 consecutive days every 28 days (one course). Results: Thirty-eight patients (23 males; median age, 7.2 years) received a median of two courses (range, one to 15). Dose-limiting grade 3 or 4 toxicities occurred in four of 36 evaluable patients and were characterized by cough, asthenia, sensory neuropathy, anorexia, serum sickness, and hypertensive encephalopathy. The most common non–dose-limiting grade 3 or 4 toxicities during course one were pain (68%) and fever (21%). Six of 31 patients evaluable for response by iodine-123 metaiodobenzylguanidine score had objective responses (four complete responses; two partial responses). The first-course pharmacokinetics of hu14.18K322A were best described by a two-compartment linear model. Median hu14.18K322A α (initial phase) and β (terminal phase) half-lives were 1.74 and 21.1 days, respectively. Conclusion: The MTD, and recommended phase II dose, of hu14.18K322A is 60 mg/m 2 per day for 4 days. Adverse effects, predominately pain, were manageable and improved with subsequent courses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.50.4423

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 165

Metadata

Authors
Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., Goldberg, J., Hank, J. A., Billups, C. A., Wu, J., Furman, W. L., McGregor, L. M., Otto, M., Gillies, S. D., Handgretinger, R., & Santana, V. M.
Venue
Journal of Clinical Oncology
Published
2014-05-10
Volume
32
Issue
14
Pages
1445-1452
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2155614959
Cited by
165
References
3
FWCI
10.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma. https://app.cochat.ai/papers/10.1200/jco.2013.50.4423
The paper
Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., Goldberg, J., Hank, J. A., Billups, C. A., Wu, J., Furman, W. L., McGregor, L. M., Otto, M., Gillies, S. D., Handgretinger, R., & Santana, V. M. (2014). Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.50.4423

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.